

Cover Story
Conversation with The Cancer Letter
By Claire Marie Porter and Paul Goldberg
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
Cancer Policy
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years
- NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown
- Most Favored Nation drug pricing could put China on top
- Protecting the cure: Why the future of radiation oncology must be precision-guided














